Trials Sponsors Conditions Drugs Pricing

Conditions

Hairy Cell Leukemia

Outcome Measures

Primary Outcomes (3)

Progression Free Survival (PFS)
Progression Free Survival (PFS)
through study completion, an average of 4 years
Time to next treatment
Time to next treatment
through study completion, an average of 4 years
Correlation between the share of mutated allele (fractional abundance) with the response to the treatment.Correlation between the share of mutated allele (fractional abundance) with the response to the treatment.
Correlation between the share of mutated allele (fractional abundance) with the response
through study completion, an average of 4 years

Secondary Outcomes (1)

mutational pattern of B-raf i
through study completion, an average of 4 years

Study Arms (1)

HCL, B-raf V600E-mutated patients

OTHER

For each patient only pheripheral and medullary blood sample and medullary biospy will be collected

Other: Peripheral and BM blood sample

Interventions

Peripheral and BM blood sampleOther

Peripheral and BM blood samples will be analyzed with the ddPCR method

HCL, B-raf V600E-mutated patients

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Histologically confirmed diagnosis of HCL patients:
newly diagnosed and candidates for first-line cytoreductive treatment with analogues purines or

Sponsors & Collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Otherlead

Study Sites (1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna

Bologna, Bologna, 40138, Italy

RECRUITING

Pier Luigi Zinzani, MDCONTACT+390512143680 pierluigi.zinzani@unibo.it

Alessandro Broccoli, MDCONTACT+39 0512143680 Alessandro.broccoli@studio.unibo.it

Pier Luigi Zinzani, MDCONTACT

MeSH Terms

Conditions

Leukemia, Hairy Cell

Condition Hierarchy (Ancestors)

LeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

Pier Luigi Zinzani, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
PRINCIPAL INVESTIGATOR

Central Study Contacts

Pier Luigi Zinzani, MD

CONTACT

+390512143680 pierluigi.zinzani@unibo.it

Alessandro Broccoli, MD

CONTACT

+39 0512143680

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: PREVENTION
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 3, 2024

First Posted

January 17, 2025

Study Start

January 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

November 2025

Estimated (date passed)

Assessment of Disease Burden in Hairy Cell Leukemia

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (1)

Study Arms (1)

HCL, B-raf V600E-mutated patients

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (1)

Study Arms (1)

HCL, B-raf V600E-mutated patients

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations